|
Volumn 20, Issue 1, 2012, Pages 422-434
|
Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists
|
Author keywords
1 Arylmethyl 4 phenylpyrrole derivatives; Androgen receptor antagonists; Castration resistant prostate cancers
|
Indexed keywords
1 [[6 CHLORO 5 (HYDOXYMETHYL)PYRIDIN 3 YL]METHYL] 4 (CYANOPHENYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBONITRILE;
1 NITRO 4 [(1E) 2 NITRO 1 PROPENYL]BENZENE;
2,5 DIMETHYL 3 (4 NITROPHENYL) 1H PYRROLE;
4 (4 CYANOPHENYL) 2 METHYL 1H PYRROLE 3 CARBONITRILE;
4 (4 CYANOPHENYL) 2 METHYL 1H PYRROLE 3 CARBOXAMIDE;
4 (4 CYANOPHENYL) 2 METHYL 1H PYRROLE 3 CARBOXYLIC ACID;
4 (4 CYANOPHENYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBONITRILE;
4 (4 CYANOPHENYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE;
4 (4 CYANOPHENYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID;
4 (4 CYANOPHENYL) 5 METHYL 1H PYRROLE 3 CARBONITRILE;
4 PHENYLPYRROLE DERIVATIVE;
4[(1E) 2 NITRO 1 ETHENYL]BENZONITRILE;
[1 BENZYL 4 (METHOXYCARBONYL) 2,5 DIMETHYL 1H PYRROL 3 YL]BORONIC ACID;
ANDROGEN RECEPTOR;
ANDROGEN RECEPTOR ANTAGONIST;
BENZYL 4 (4 CYANOPHENYL) 2 METHYL 1H PYRROLE 3 CARBOXYLIC ACID;
BICALUTAMIDE;
ETHYL 1 (CYCLOHEXYLMETHYL) 2,5 DIMETHYL 4 (4 NITROPHENYL) 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 1,2,5 TRIMETHYL 4 (4 NITROPHENYL) 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1 (2 PHENYLETHYL) 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1 (PHENYLCARBONYL) 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1 (PHENYLSULFONYL) 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1 PHENYL 1H PYRROLE 3 CARBOXYLIC ACID;
ETHYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1H PYRROLE 3 CARBOXYLIC ACID;
METHYL 1 BENZYL 4 BROMO 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID;
METHYL 4 (4 CYANOPHENYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID;
METHYL 4 BROMO 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID;
PROSTATE SPECIFIC ANTIGEN;
TERT BUTYL 2,5 DIMETHYL 4 (4 NITROPHENYL) 1H PYRROLE 3 CARBOXYLIC ACID;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
BINDING AFFINITY;
CANCER INHIBITION;
CASTRATION RESISTANT PROSTATE CANCER;
CONTROLLED STUDY;
DRUG BIOAVAILABILITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG SCREENING;
DRUG SOLUBILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IC 50;
MONOTHERAPY;
MOUSE;
NONHUMAN;
PROSTATE CANCER;
PROTEIN BLOOD LEVEL;
RECEPTOR BINDING;
STRUCTURE ACTIVITY RELATION;
TUMOR VOLUME;
TUMOR XENOGRAFT;
WEIGHT REDUCTION;
AMINO ACID SUBSTITUTION;
ANDROGEN RECEPTOR ANTAGONISTS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CELL LINE, TUMOR;
DRUG DESIGN;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
MALE;
MICE;
MICE, INBRED ICR;
MICE, NUDE;
MUTATION;
PROSTATIC NEOPLASMS;
PYRROLES;
RECEPTORS, ANDROGEN;
TRANSPLANTATION, HETEROLOGOUS;
|
EID: 84855191808
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2011.10.067 Document Type: Article |
Times cited : (23)
|
References (38)
|